Wolfe Research upgraded Guardant Health (GH) to Outperform from Peer Perform with a $75 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $80 from $70 at UBS
- Guardant Health’s Strategic Advancements and Growth Potential Earns Buy Rating
- Guardant Health Hosts Investor Day in NYC
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Guardant Health: Buy Rating Backed by Growth Potential and Innovation in Cancer Screening